Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-N230A PET/CT Imaging in Renal Tumors
NCT07875959Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of 18F-N230A in renal cell carcinoma (RCC) and Renal Pelvic Urothelial Carcinoma (RPUC), sponsored by Peking University First Hospital. Primary endpoint: Diagnostic Accuracy of 18F-N230A PET/CT up to 2 months. Started Jul 2026; status: recruiting.
02
Drugs
18F-N230A
03
Conditions
renal cell carcinoma (RCC)Renal Pelvic Urothelial Carcinoma (RPUC)
Beyond the preview
Go deeper on NCT07875959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875959.